Omnicell (OMCL)
(Delayed Data from NSDQ)
$32.63 USD
+0.93 (2.93%)
Updated May 24, 2024 04:00 PM ET
After-Market: $32.68 +0.05 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Omnicell, Inc. [OMCL]
Reports for Purchase
Showing records 101 - 120 ( 326 total )
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Bull vs. Bear Case; See 110% Upside and 13% Downside from Current Levels
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Reducing Workforce by ~9%; Expect ~7.5% Positive Impact to Annual Adj. Profits
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
3Q Miss; FY Guidance Lowered by 8% on Revenues and 28% on Adj. EBITDA
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Miss + Substantial Guide Down:Valuation Implies Troughing Setup (ex. Great Recession);Remain OW
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Reiterated 2025 Revenue Targets, but Margin Targets Lowered ~100 bps
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department